Inactive Instrument

News Clearmind Medicine Inc. Canadian Securities Exchange

Equities

Clearmind Applies to Cease Being a Reporting Issuer in Canada	Apr. 30	AQ
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	Apr. 17	AQ
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	Apr. 10	AQ
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	Apr. 10	CI
Clearmind Medicine CEO Issues Letter to Shareholders	Apr. 09	AQ
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	Mar. 27	CI
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	Mar. 19	AQ
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	Mar. 19	CI
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	Mar. 19	PU
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 18	CI
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	22-03-08	PR
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	21-10-14	GL
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	21-10-01	GL

No results for this search